PT3285772T - Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren - Google Patents

Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren

Info

Publication number
PT3285772T
PT3285772T PT167193564T PT16719356T PT3285772T PT 3285772 T PT3285772 T PT 3285772T PT 167193564 T PT167193564 T PT 167193564T PT 16719356 T PT16719356 T PT 16719356T PT 3285772 T PT3285772 T PT 3285772T
Authority
PT
Portugal
Prior art keywords
sjã
gren
trifluoroethyl
syndrome
treatment
Prior art date
Application number
PT167193564T
Other languages
English (en)
Portuguese (pt)
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of PT3285772T publication Critical patent/PT3285772T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT167193564T 2015-04-21 2016-04-20 Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren PT3285772T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use

Publications (1)

Publication Number Publication Date
PT3285772T true PT3285772T (pt) 2020-01-14

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167193564T PT3285772T (pt) 2015-04-21 2016-04-20 Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55546B1 (sr) * 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
PL2137186T3 (pl) * 2007-03-23 2016-09-30 Związki heterocykliczne i ich zastosowania
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
US20180092921A1 (en) 2018-04-05
EP3285772A1 (en) 2018-02-28
JP2018513862A (ja) 2018-05-31
EP3285772B1 (en) 2019-10-02
MX2017013148A (es) 2018-02-21
BR112017020591B8 (pt) 2023-05-16
BR112017020591A2 (pt) 2018-07-03
BR112017020591B1 (pt) 2023-02-07
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
CN107530344A (zh) 2018-01-02
HRP20192273T1 (hr) 2020-03-06
KR102627370B1 (ko) 2024-01-18
US10493074B2 (en) 2019-12-03
SG11201707789YA (en) 2017-11-29
DK3285772T3 (da) 2020-01-13
EA201792318A1 (ru) 2018-05-31
LT3285772T (lt) 2020-01-10
ES2763335T3 (es) 2020-05-28
MY192972A (en) 2022-09-20
IL254766A0 (en) 2017-12-31
CL2017002669A1 (es) 2018-05-11
CA2981631C (en) 2023-02-21
GB201506786D0 (en) 2015-06-03
CY1122572T1 (el) 2021-01-27
AU2016251236A1 (en) 2017-11-09
IL254766B (en) 2020-05-31
CO2017010573A2 (es) 2018-03-09
AU2016251236B2 (en) 2018-06-14
SI3285772T1 (sl) 2020-02-28
AR105552A1 (es) 2017-10-18
PL3285772T3 (pl) 2020-05-18
CN107530344B (zh) 2020-03-17
KR20170140245A (ko) 2017-12-20
WO2016170014A1 (en) 2016-10-27
JP6721606B2 (ja) 2020-07-15
CA2981631A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL271492A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL262943A (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
GB201704188D0 (en) Myopic sunglasses
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL247969B (en) A medicinal component for use in the treatment of infections
PT3285772T (pt) Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PT3229780T (pt) Composições oftálmicas para utilização no tratamento da síndrome de olhos secos
PL3250181T3 (pl) Formulacja farmaceutyczna na bazie minoksydylu do stosowania miejscowego i jej zestaw
GB201400370D0 (en) Polyarylethereketone prosthodontics device in the form of an inlay or onlay
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
AU2014902872A0 (en) Bowler's arm
AU2014901914A0 (en) Bowler's arm
GB201412638D0 (en) Artist's implement
GB201500543D0 (en) The Edward's chronometer
ZA201408464B (en) Composition for the use in treatment of asthma